CRIXIVAN CAPSULE
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
30-10-2015
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
INDINAVIR (INDINAVIR SULFATE)
から入手可能:
MERCK CANADA INC
ATCコード:
J05AE02
INN（国際名）:
INDINAVIR
投薬量:
400MG
医薬品形態:
CAPSULE
構図:
INDINAVIR (INDINAVIR SULFATE) 400MG
投与経路:
ORAL
パッケージ内のユニット:
90/120/180
処方タイプ:
Prescription
治療領域:
HIV PROTEASE INHIBITORS
製品概要:
Active ingredient group (AIG) number: 0133330002; AHFS:
認証ステータス:
CANCELLED POST MARKET
承認日:
2016-11-01
製品の特徴
_ _
_CRIXIVAN_
®
_ (indinavir sulfate) _
_Page 1 of 45_
PRODUCT MONOGRAPH
PR
CRIXIVAN
®
indinavir capsules
400 mg
(as indinavir sulfate)
HIV Protease Inhibitor
MERCK CANADA INC.
16750 route Transcanadienne
Kirkland, QC Canada H9H 4M7
www.merck.ca
Date of Revision:
October 29, 2015
SUBMISSION CONTROL NO: 185534
_ _
_CRIXIVAN_
®
_ (indinavir sulfate) _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
21
OVERDOSAGE
................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 22
STORAGE AND STABILITY
.........................................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
26
PHARMACEUTICAL INFORMATION
.........................................................................
26
CLINICAL TRIALS
.........................................................................................................
27
DE
完全なドキュメントを読む
